Furthermore, the neuroprotective and anti-inflammatory effects of SIRT 2 inhibition in vitro, and the maintained expression level of this HDAC in the degenerating SNpc in the Parkinsonian brain, highlight the therapeutic potential of targeting this HDAC for disease modification in PD. Here, HDAC9 is linked to Parkinson disease.